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Abstract
Background: Lung cancer is the second most common cancer and the leading cause of cancer death for both
men and women. Although low-dose CT (LDCT) is recommended for lung cancer screening in high-risk populations and
may decrease lung cancer mortality, there is a need to improve the accuracy of lung cancer screening to decrease over-
diagnosis and morbidity. Blood and serum-based biomarkers, including EarlyCDT-lung and microRNA based biomarkers,
are promising adjuncts to LDCT in lung cancer screening.
We evaluated the diagnostic performance of EarlyCDT-lung, micro-RNA signature classifier (MSC), and miR-test, and their
impact on lung cancer-related mortality and all-cause mortality.
Methods: References were identified using searches of PubMed, EMBASE, and Ovid Medline® from January 2000
to November 2015. Phase three or greater studies in the English language evaluating the diagnostic performance
of EarlyCDT-lung, MSC, and miR-test were selected for inclusion.
Results: Three phase 3 studies were identified, one evaluating EarlyCDT-lung, one evaluating miR-Test, and one
evaluating MSC respectively. No phase 4 or 5 studies were identified. All three biomarker assays show promise for
the detection of lung cancer. MSC shows promise when used in conjunction with LDCT for lung cancer detection,
achieving a positive likelihood ratio of 18.6 if both LDCT and MSC are positive, and a negative likelihood ratio of 0.03 if both
LDCT and MSC are negative. However, there is a paucity of high-quality studies that can guide clinical implementation.
Conclusions: There is currently no high quality evidence to support or guide the implementation of these biomarkers in
clinical practice. Reports of further research at stages four and five for these, and other promising methods, is required.
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Background
Lung cancer is the second most common cancer and the
leading cause of cancer death for both men and women
[1–3]. In 2015, an estimated 26,600 Canadians were diag-
nosed with, and 20,900 died from, lung cancer [2]. In 2014,
163,422 patients from the UK died from lung cancer, with
lung cancer projected to continue as the leading cause of
cancer-related death until 2035 [3]. The five year survival
rate for patients diagnosed with late stage lung cancer and
metastatic lung cancer are 16.8% and < 5% respectively [1].
Conversely, the 5-year survival rate of small intrapulmon-
ary cancers is 80% [4]. Therefore, identification of lung
cancer at an early stage could potentially lead to significant
decreases in morbidity and mortality [5, 6].
In 2010, the National Lung Screening Trial (NLST)
demonstrated a 20% reduction in lung cancer mortality
and 7% reduction in all-cause mortality by screening pa-
tients at high risk of lung cancer with low-dose chest
CT (LDCT) scans (NNS = 320) [1, 4]. However, 24.2% of
patients who had LDCT exhibited abnormal findings,
and 96.4% of these findings were false positive results,
representing a 18% over-diagnosis rate [1, 4, 7]. The high
rate of false positives has led to multiple screening
rounds with high radiation exposure, a high use of
harmful diagnostic follow-up, increased patient costs
and anxiety [4, 8]. Therefore, while LDCT may be effect-
ive in reducing lung cancer mortality, there is a need to
improve the accuracy of lung cancer screening to de-
crease morbidity and health-care associated costs.
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Molecular biomarkers are potentially useful adjuncts to
LDCT for lung cancer screening, either by further delin-
eating patient risk prior to LDCT, or assessing malignant
risk of positive LDCT findings [1, 4, 6, 9, 10]. The per-
formance of any test also depends upon the prior prob-
ability of the condition in the population being sampled
and this varies considerably [11, 12]. Biomarkers may be
generated from cancer cells, the tumor microenviron-
ment, or the host response to cancer [4, 13]. Various mo-
lecular factors that are implicated in lung carcinogenesis
have been evaluated as prognostic and diagnostic bio-
markers, such as markers of apoptosis, cellular adhesion,
cellular growth, and tumor proliferation [10, 14]. Epigen-
etic markers such as DNA methylation, miRNAs, nucleo-
some remodeling, and histone modifications have also
been investigated [10, 13, 14]. Biomarkers may be sampled
from many different bodily sources, including whole
blood, serum, plasma, bronchial brushings, and sputum
[13, 14]. Circulating blood-based and serum-based bio-
markers are a convenient compartment to sample as they
are relatively easy and inexpensive to collect [4, 6, 9].
The EarlyCDT-Lung test is a commercially available
blood test based on ELISA principles that measures a
panel of seven tumor-associated autoantibodies: p53,
NY-ESO-1, CAGE, GBU4–5, SOX2, HuD, and MAGE
A4 [15]. The miR-test is a serum based miRNA test that
measures a signature of 13 miRNAs: miR-92a-3p, miR-
30b-5p, miR-191-5p, miR-484, miR-328-3p,miR-30c-5p,
miR-374a-5p, let-7d-5p, miR-331-3p, miR-29a-3p, miR-
148a-3p, miR-223-3p, miR-140-5p [16]. The MSC is a
plasma-based miRNA test that categorizes patients into
low, intermediate, or high risk of disease based on pre-
defined positivity for 24 miRNA expression ratios [17].
Of the available blood and serum-based biomarkers, only
EarlyCDT-Lung, Serum-based miRNA signature (miR-
test), and Plasma-based miRNA test (MSC) have entered
Phase 4 of development [4]. There is, therefore, a need
to evaluate the current state of biomarker development,
especially EarlyCDT-Lung and miRNA based strategies,
to guide future research in lung-cancer screening.
This literature review describes the diagnostic per-
formance of EarlyCDT-Lung, miR-test, and MSC as ad-
junctive biomarkers to LDCT for the diagnosis of lung
cancer. The key questions considered for this review are:
1. What is the individual diagnostic performance of
each of EarlyCDT-Lung, miR-test, and MSC for the
detection of lung cancer?
2. What is the diagnostic performance of EarlyCDT-
Lung, miR-test, and MSC used in conjunction with
LDCT for the detection of lung cancer?
3. Does screening with EarlyCDT-Lung, miR-test, and
MSC with or without LDCT improve lung-cancer
mortality and all-cause mortality?
Methods
Search strategy
A literature review was conducted at North York General
Hospital, a suburban academic teaching hospital in Toronto,
Canada. We searched Ovid MEDLINE ®, EMBASE, and
PUBMED from 2000 up to November 2015 for any lung can-
cer diagnostic trials involving EarlyCDT-Lung, miR-test, and
MSC published in English. We also checked reference lists of
included studies and relevant systematic reviews. The full
search strategy is available in Additional file 1: Appendix 1.
Study selection
After removing duplicates, all citations titles were evalu-
ated for relevance utilizing inclusion criteria for this re-
view. Citation titles were evaluated independently by GS
and FS, with consensus amongst both PIs required for
inclusion. Articles marked for inclusion by either team
member went on to abstract relevance testing. Abstract
screening was done independently by GS and FS, with
consensus required for inclusion or exclusion.
Inclusion and exclusion criteria
Language
The published results of studies had to be available in
English.
Population
The population of interest for the review was asymptom-
atic adults age 18 and older who were at high risk but
were not suspected of having lung cancer. Patients known
to have lung cancer or were previously diagnosed with
lung cancer were excluded from the study population.
Interventions
The three screening interventions of interest were:
1. EarlyCDT-Lung, an antibody based biomarker
screening panel
2. miR-test, a serum-based 13 miRNA signature
3. micro-RNA signature classifier (MSC), a plasma-
based 24 miRNA risk score
Study design
To answer the key questions, only Phase 3 or Phase 4
studies that included one or more measures of diagnostic
performance (sensitivity, specificity, likelihood ratio, etc)
in the abstract were included. All studies that were Phase
1, Phase 2, or did not mention any diagnostic performance
measure were excluded.
Outcomes
The key outcomes evaluated in this review included:
1. Diagnostic performance for detection of lung cancer
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2. Outcome performance in reducing lung cancer-
related mortality and all-cause mortality
Data abstraction and assessment of study validity
For each included study, we extracted data about the
population, study design, intervention, inclusion criteria,
exclusion criteria, the analysis, and results for the out-
come of interest. To evaluate for validity and bias, each
included study was evaluated against the STARD 2015
checklist [18]. Any concerns regarding bias or the valid-
ity of the study was recorded in the data collection tem-
plate. The full data collection template is available in
Additional file 1: Appendix 2.
Results
Summary of literature search
Our search for studies examining the diagnostic and
outcome performance of EarlyCDT-lung, miR-test, and
MSC with and without LDCT located 99 unique cita-
tions (Fig. 1). From these searches, we identified 28 re-
view articles on the topic of biomarkers for lung-cancer
screening. On-topic non-review studies were identified
for abstract screening. 12 of the remaining 15 studies
were excluded for being Phase 1 or 2 trials and did not
meet the inclusion criterion of Phase 3 and above. 56
studies were excluded because the paper described inter-
ventions or outcome which used biomarkers and 12
were excluded because the study design did not enable
the calculation of test performance characteristics.
The reference lists of included studies and identified
review articles were examined, but no additional studies
that met inclusion criteria were identified. Therefore, 3
identified studies met inclusion criteria and were in-
cluded in the review.
Summary of included studies
Three phase 3 studies evaluated the diagnostic perform-
ance of various blood-based biomarkers for lung cancer
detection, one evaluating EarlyCDT-lung [19], one evalu-
ating miR-Test [16], and one evaluating MSC [17] re-
spectively. No phase 4 or 5 studies were identified.
Although all three studies were phase 3 studies, inclu-
sion criteria and study design differed significantly. A
summary of study characteristics is available in Table 1.
A full summary of each included study is available in
Additional file 1: Appendix 3.
Jett et al. evaluated the use and diagnostic perform-
ance of EarlyCDT-lung in 1613 patients presenting to
810 unique physicians in 720 different practices in 48
states [19]. The EarlyCDT-Lung test was offered to pa-
tients at the discretion of the treating physician. Clear
inclusion/exclusion criteria for whom to offer the test
were not stated. The definition for a positive screening
result included any antigen titration series showing a
dose response and one or more auto-antibodies resulting
above the previously validated clinical cut-off. Patients
were followed for a period of 6 months and the treating
physician decided on a lung cancer diagnosis. Confirm-
ation by an external lung cancer expert was sought if
evidence challenging the diagnosis was found.
Sozzi et al. evaluated the diagnostic performance of
the MSC in 1000 consecutive plasma samples from 4099
participants enrolled in the Multicenter Italian Lung De-
tection (MILD) Trial [17]. The MILD trial was a RCT
involving 4099 current or former smokers of greater
than 20 pack-years and at least 50 years of age without
history of cancer in the past year, evaluating the effective-
ness of LDCT for lung cancer screening; 2376 enrolled pa-
tients were randomly assigned to the LDCT arms and
Fig. 1 Search and selection results
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1723 to the observation arm [20]. 130 of the 1000 plasma
samples collected were excluded due to hemolysis. 69
samples from the 85 patients identified with lung cancer
in the entire MILD trial were included, resulting in a total
number of 939 plasma samples. Patients were followed for
a period of 5 years as part of the MILD trial.
Montani et al. evaluated the diagnostic performance of
the miR-test in a “validation set” of 1008 patients enrolled
in the Continuous Observation of Smoking Subjects
(COSMOS) trial and lung cancer patients diagnosed out-
side of the screening trial [16]. The COSMOS trial is an
ongoing observational trial evaluating LDCT screening in
patients greater than 50 years old with a greater than 20
pack-year smoking history and without any diagnosed pul-
monary pathology [21]. 1008 individuals enrolled in the
COSMOS study including 36 patients with low-dose com-
puted tomography (LDCT)-detected lung cancer and 972
individuals without lung cancer, randomly selected from
the entire COSMOS consecutive cohort from March 2011
to March 2012 were included in this study.
Diagnostic performance for detection of lung cancer
The diagnostic performance of each biomarker test used
alone for the detection of lung cancer is summarized in
Table 2. EarlyCDT-lung showed a sensitivity, specificity,
PPV, NPV, and positive likelihood ratio of 41%, 87%,
11%, 97%, and 3.19 respectively. MSC had a sensitivity,
specificity, PPV, NPV, and positive likelihood ratio of
87%, 81%, 27%, 98%, and 4.67 respectively. miR-test had
a sensitivity, specificity, PPV, NPV, and positive likeli-
hood ratio of 78%, 75%, 10%, 98%, and 3.09 respectively.
The MSC was evaluated for its diagnostic performance
in conjunction with LDCT. If positive results for both
MSC and LDCT were needed for a positive screen, a
sensitivity, specificity, PPV, NPV, and positive likelihood
ratio of 69%, 96%, 65%, 97%, and 18.6 was achieved. If
only one of MSC or LDCT needed to be positive to re-
sult in a positive screen, a sensitivity, specificity, PPV,
NPV, and negative likelihood ratio of 98%, 66%, 22%,
99%, and 0.03 was achieved.
Lung cancer-related mortality and all-cause mortality
miR-test and MSC were evaluated for the important out-
come of lung-cancer related mortality (Table 3). The miR-
test had a sensitivity, specificity, PPV, NPV, and positive
likelihood ratio of 100%, 73%, 1%, 100%, and 3.72 respect-
ively for lung cancer-related mortality. The MSC had a
sensitivity, specificity, PPV, NPV, and positive likelihood
ratio of 95%, 78%, 8%, 99%, and 4.27 respectively for lung
cancer-related mortality. There were a total of 3 lung-
cancer deaths in the study evaluating miR-test and 19
lung-cancer deaths in the study evaluating MSC.
The MSC was evaluated for overall mortality. How-
ever, no death occurred due to other causes in lung can-
cer–free participants.
Table 1 Summary of study characteristics
Jett et al. 2014 Sozzi et al. 2014 Montani et al. 2015
Test Evaluated EarlyCDT-lung MSC miR-test
Number of patients 1613 939 1008
Patient Inclusion Criteria EarlyCDT-lung test made available
to treating physicians Clear inclusion
criteria not defined
MILD trial participants: > 20
pack-years smoking history
> 50 years old without history
of cancer in past 5 years.
1000 consecutive plasma
samples from trial participants
Additional 69 plasma samples
from 85 patients with lung
cancer in MILD trial
COSMOS trial participants:
> 20 pack-years smoking
> 50 years old Lung cancer patients
diagnosed outside of COSMOS trial
Patient Exclusion Criteria Clear exclusion criteria not defined Hemolyzed samples No known
pulmonary pathology
No known pulmonary pathology
Follow-up Period 6 months 5 years Unknown
Key Study limitations Audit trial used in regular physician
practice
No clear eligibility criteria
No clear lung cancer diagnostic criteria
No baseline characteristics of population
No distribution of alternative diagnosis
in those without target condition
No discussion of study limitations,
biases, uncertainty
No link to full study protocol
No discussion of sources of funding
No discussion of how sample
size was determined
No distribution of alternative
diagnosis for those without
lung cancer
No indication of whether clinical
information available to performers/
readers of tests
No discussion of how sample size
was determined
No distribution of alternative diagnosis
in those not diagnosed with lung cancer
Very brief discussion of study limitations
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Discussion
EarlyCDT-lung, miR-test, and MSC were chosen as the
focus for this review as they are reported as the bio-
markers at the most advanced phase of development for
the detection of lung cancer [4]. This review focuses on
clinically relevant measures for lung cancer screening, in-
cluding measures of diagnostic performance and impact
on lung cancer-related mortality and all-cause mortality.
All three biomarkers show promise in their diagnostic
ability to detect lung cancer. The plasma-based micro-
RNA signature classifier (MSC) trended towards the high-
est sensitivity, specificity, and positive likelihood ratio for
the detection of lung cancer. However, a direct compari-
son between the three biomarker signatures cannot be
made at this time as sample sizes are small, confidence in-
tervals for performance measures are wide, no trials have
directly compared the three biomarker signatures, and the
number of trials evaluating each biomarker is singular.
The only trial that directly evaluated the diagnostic abil-
ity of a blood-based biomarker in conjunction with LDCT
shows promise that biomarkers can be useful adjuncts to
LDCT in screening for lung cancer. When using MSC in
conjunction with LDCT, a positive likelihood ratio of 18.6
was achieved if both MSC and LDCT were positive, while
a negative likelihood ratio of 0.03 was achieved if both
MSC and LDCT were negative. This suggests that bio-
marker signatures may potentially be a means to risk strat-
ify at-risk patients for the development of lung cancer.
Although blood-based biomarkers show promise, there
currently is no high quality prospective literature to guide
the implementation of blood-based biomarkers in clinical
practice for lung cancer detection. Prospective phase 4
studies are currently ongoing to assess the value of the
above biomarkers for their value as a pre-CT screening
tool. The Early Lung Cancer Detection Study (ECLS) is
currently ongoing in Scotland, randomizing approximately
12,000 people from the Greater Glasgow and Clyde area to
the EarlyCDT-lung test or routine care (ClinicalTrials.gov
ID: NCT01925625) [22]. Patients with a positive Early-
CDT-lung test undergo a CT scan at baseline followed by
CT scans every 6 months for 24 months. The primary out-
come is the difference at 24 months in the number of pa-
tients with late stage lung cancer (Stages 3 and 4). The
COSMOS II study enrolling approximately 10,000 high
risk subjects in Italy will evaluate prospectively miR-Test in
conjunction with LDCT [16]. Similarly, the Plasma micro-
RNA Profiling as First Line Screening Test for Lung Can-
cer Detection (BIOMILD) trial will enroll approximately
4000 subjects to evaluate the MSC as a potential first line
screening test for lung cancer (ClinicalTrials.gov ID:
NCT02247453) [23].
Limitations of this work include the small number of
studies identified and the substantial variability across stud-
ies in terms of inclusion criteria, methodology, follow-up,
timing, and comparators. The number of patients enrolled
was small and follow up period for each study was rela-
tively short. It is important to note that the inclusion cri-
teria for these studies varied regarding pack-years of
smoking and how patients were enrolled from their larger
parent trials. These trials were conducted in different
countries where attitudes, laws, and public health policies
regarding smoking differed. As our search focused on the
three biomarker signatures (EarlyCDT-Lung, miR-test, and
MSC), studies regarding other biomarker signatures would
not have been included. Finally, studies published in lan-
guages apart from English would not have been included.
Conclusions
Although blood and serum-based biomarkers are prom-
ising adjuncts to LDCT for the detection lung cancer,
there is currently no high quality evidence to support or
guide the implementation of these biomarkers in clinical
practice. Prospective studies are ongoing to evaluate the
diagnostic performance and impact of biomarkers on
clinically relevant outcomes. Further research is required
to guide clinical implementation.
Table 3 Diagnostic performance of biomarkers alone for lung-
cancer death
Test Evaluated MSC miR-test
Sensitivity 95% (95%CI: N/A) 100% (95%CI: N/A)
Specificity 78% (95% CI: 75–80%) 73% (95% CI: 70–76%)
PPV 8% (95% CI: 5–12%) 1.1% (95% CI: N/A)
NPV 99% (95% CI: N/A) 100% (95% CI: N/A)
Positive LR 4.27 3.72
Table 2 Diagnostic performance of biomarkers alone for detection of lung cancer
Test Evaluated EarlyCDT-lung MSC miR-test
Sensitivity 41% (95% CI: 29–53%) 87% (95%CI: N/A) 78% (95%CI: N/A)
Specificity 87% (95% CI: 86–89%) 81% (95% CI: 79–84%) 75% (95% CI: 72–78%)
PPV 11% (95% CI: 7–15%) 27% (95% CI: 21–32%) 10% (95% CI: 7–14%)
NPV 97% (95% CI: 97–98%) 98% (95% CI: N/A) 98% (95% CI: N/A)
Positive LR 3.19 4.67 3.09
Negative LR 0.68 0.16 0.30
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